medical marijuana (Roxana Gonzalez on Shutterstock)

Tilray Medical, a division of Tilray Brands, Inc. TLRY TLRY announced on Wednesday the launch of Redecan EU-GMP certified medical <a href="https://www.benzinga.com/topic/australia">cannabis products in Australia</a>.



What Happened: The following&nbsp;Redecan&nbsp;products are now available for medical cannabis patients in&nbsp;Australia, including:



<ul>
<li>Redecan PC THC28 Purple Churro – 15g</li>



<li>Redecan SA THC28 Space Age Cake – 15g</li>
</ul>



Why It Matters: Denise Faltischek, chief strategy officer and head of international at Tilray Brands, praised the move.



Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28597648/tilrays-cbd100-approved-for-clinical-trials-in-australia-and-new-zealand-by-the-natural-health-s">Tilray&#8217;s CBD100 Approved For Clinical Trials In Australia And New Zealand By The Natural Health Science Foundation</a>



<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>



"The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions," Faltischek said.



<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18084431/ccc-oct-24-banner__1_-26.gif" alt="" class="wp-image-553913"/></a></figure>



Jonathan Trodden, director at Tilray Medical Australia, agrees: "We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.&#8221;



Tilray has been present in Australia for years. In 2022, the company launched a new medical cannabis e-learning platform for healthcare providers, built on the importance of understanding the benefits derived <a href="https://www.benzinga.com/markets/cannabis/22/01/25204825/tilray-expands-medical-marijuana-product-offering-in-australia-launches-cannabis-e-learning-plat">from medical cannabis use</a>. This effort followed Tilray&#8217;s successful introduction of multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of healthcare practitioners in 2021.



Price Action: Tilray's shares traded 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here&#8217;s Why</a></li>
</ul>

Cannabis

News

Retail Sales

Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia - Tilray Brands (NASDAQ:TLRY)

Jelena Martinovic

Tilray Brands

Australia

Australia Cannabis

Denise Faltischek

Jonathan Trodden

medical cannabis

medical marijuana

Redecan

Tilray Medical

TLRY

TSX:TLRY

Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia

Tilray Brands Inc

Application error: a client-side exception has occurred (see the browser console for more information).